Women Deemed Inoperable For Breast Cancer Benefited From IceCure Medical's ProSense As An Independent Study Performed In Italy Showed A Tumor Reduction Rate Of 93.43% To 96.81%
Portfolio Pulse from Benzinga Newsdesk
An independent study in Italy has shown that IceCure Medical's ProSense has a tumor reduction rate of 93.43% to 96.81% in women deemed inoperable for breast cancer. The Luminal-A group showed no residual malignant cells, indicating the complete effectiveness of the treatment.
October 05, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The positive results from the independent study on IceCure Medical's ProSense could boost the company's reputation and potentially increase demand for its product.
The news of the successful independent study on IceCure Medical's ProSense is directly related to the company and its product. This could lead to increased demand for ProSense, potentially driving up the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100